301. Macular dystrophy
41 clinical trials,   47 drugs   (DrugBank: 12 drugs),   12 drug target genes,   66 drug target pathways

Searched query = "Macular dystrophy", "Best disease", "Stargardt disease", "Cone dystrophy", "Cone rod dystrophy", "X-linked juvenile retinoschisis", "Central areolar choroidal dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-004783-35-DE
(EUCTR)
10/07/201823/01/2018A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt DiseaseA Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease Autosomal Recessive Stargardt Disease
MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: Zimura
Product Code: ARC1905
INN or Proposed INN: avacincaptad pegol
Other descriptive name: ARC1905 20 MG/ML
IVERIC bioNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
70Phase 2United States;France;Hungary;Canada;Spain;Israel;Germany;United Kingdom;Italy
2EUCTR2017-004783-35-GB
(EUCTR)
29/05/201826/01/2018A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt DiseaseA Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease Autosomal Recessive Stargardt Disease
MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: Zimura
Product Code: ARC1905
INN or Proposed INN: avacincaptad pegol
Other descriptive name: ARC1905 20 MG/ML
IVERIC bioNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
70Phase 2United States;France;Hungary;Canada;Spain;Israel;Germany;Italy;United Kingdom
3EUCTR2017-004783-35-ES
(EUCTR)
09/04/201802/02/2018A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt DiseaseA Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease Autosomal Recessive Stargardt Disease
MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: Zimura
Product Code: ARC1905
INN or Proposed INN: avacincaptad pegol
Other descriptive name: ARC1905 20 MG/ML
OPHTHOTECH CORPORATIONNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Phase 2France;United States;Hungary;Canada;Spain;Israel;Germany;Italy;United Kingdom
4EUCTR2017-004783-35-HU
(EUCTR)
21/03/201801/02/2018A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt DiseaseA Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease Autosomal Recessive Stargardt Disease
MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: Zimura
Product Code: ARC1905
INN or Proposed INN: avacincaptad pegol
Other descriptive name: ARC1905 20 MG/ML
IVERIC bioNULLNot RecruitingFemale: yes
Male: yes
70Phase 2United States;France;Hungary;Canada;Spain;Israel;Germany;United Kingdom;Italy
5NCT03364153
(ClinicalTrials.gov)
January 12, 20181/12/2017Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt DiseaseStargardt Disease 1Drug: Zimura;Other: ShamIVERIC bio, Inc.NULLRecruiting18 Years50 YearsAll120Phase 2United States;Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom